Böbrek Hastalıklarının Tedavisinde Anjiyotensin Dönüştürücü Enzim İnhibitörleri ve Anjiyotensin II Reseptör Blokerlerinin Kombinasyonu

1. Stergioıı GS, Skeva [I, Renİn-Angİolensin
syste
m blockade al the level of tile Angiotensin convening enzyme or ibe Angiotensin type-1 receptor: similarities and differences. Curr "top Med Chem. 2r leli-ventricular
TND I. Hipertansiyon Kursu 2004, 13: Ek 2 / TSN Hypertension Course I 2004, 13: Suppl 2
59
t Böbrek 1 iastalıklannırı Tedavisinde Anjiyotensin Dönüştürücü Krizini İnhibitörleri ve Anjiyotensin II Reseptör Blokerlerinin Kombinasyonu
dysfunction: a systematic overview öf data from individual patients- ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2ÖÜ0;555; 1575.
5, Ruggenenti P, Perna A. Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. J Am Soc Nephrol 2001;12:2832-2857.
0. Russo D, Pisani A, Balletta MM. el al. Additive antiproteinu-ric effect of converting enzyme inhibitor and losartan in nor-inotensive patients with IgA nephropathy. Am J Kidney Dis ]W);53: 851-
Ruilope LM, Aldigier JC, Ponticelli G. el al. Safety of the combination of valsarlan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsarlan in Chronic Renal Disease. J I ly per t ens 2000;18:89.
8. Laverman GD, Navis G. Henning Rll. el al. Dual renin-angi-olensin system blockade at optimal doses for proteinuria. Kidney Int 20O2;62:lO20.
*). Nakao N, Voshinnira A, Morila H, el al. Combination treatment of angiotensin-!! receptor blocker and angiotensin-con-verting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117.
10. Campbell R, Sangalli F, Pertieucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Ini 2003:63:1094.
I I Thurman JM, Schrier RW, Comparative effects of angiotensin-converting enzyme- inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med 2003: 114:588.
12. Yusuf S. Sleight P, Pogue J, Bosch J. Davies R, Dagenais G. Effects of an angiorensin-converting enzyme Inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2(K)l); 3 l2:l İ5-153.
13 Abboll KC. liakris GL, What have we learned from the eur-rvni trials? Med Clin North Am 200 i;K8l 11:189-207.
1 i. Pol la re T. Lithel] H, Berne, C. A comparison of the effects of hydrochlorothiazide and eaptopril on glucose and lipid metabolism İn patients with hypertension. N Engl J Med 1989; 321:86&
15 Yusuf S. Gerstein H, I loogwerf H. el al. Ramipril and the de-velopmeni of diabetes. JAMA 2001:280:1882.
Hi. Kincairi-Smilh P, Kenneth l-'airlcy, Packham D. Randomized conlrolled crossover Study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normo-tensive patients with chronic renal disease and proteinuria Nephrol Dial Transplant 2002 l 171:597-601.
17. Ruggenenti P, Perna A. Gherardi G, el al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial: Gruppö Italiano di Studi Epidemiologic! in Nefrologia ıGISEN): Ramipril Efficacy in Nephropathy. Lancet 1998^*52:1252-1256,
18. Hosteller Til. Olson JL. Rennke HG. el al. Hypeifiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:E85-F93.
19. Brenner BM, Meyer TW. Hosteller 111. Dietary protein intake and the progressive nature of kidney disease: The role of he-ıHodynanvİcaİly mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl .1 Med 1982;307:652-9.
20. Anderson S, Meyer TW, Rennke HG, et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-619.
21. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
22. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976;57:419-434.
23- Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEl to angiotensin II antagonists. Kidney Ini 2000;57:1803-1817.
24. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotension-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. New Engl J Med 2001;345:851-860.
25. Brenner B, Cooper M, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001 ;345: 861-869¬26. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of dialx-tic nephropathy in patients with type 2 diabetes. New Engl J Med 2001; 345:870-878.
27. Peterson JC, Adler S, Burkart JM, el al. Blood pressure control, proteinuria and the progression of renal disease. The modification of diet İn renal disease study. Ann Intern Med 1995; 123:754-762.
28. Agarwal R. Add-on angiotensin receptor blockade with maximised ACE inhibition. Kidney Int 2001;59:2282-2289.
29. Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of the combination of valsarlan and benazepril in patients with chronic renal disease. J Hypertension 2000;18:89-95.
30. Russo D, Pisani A, Ballelta MM, et al. Additive antiproteinu-ric effect of converting enzyme inhibitor and losartan in nor-motensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-856.
31. Zoccali C, Valvo E, Russo D, et al. Antiproteinuric effect of losartan in patients with chronic renal disease. Nephrol Dial Transplant 1997;12:234-235.
32. Mogensen CE, Neklam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hyperiension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril micro-albimiuria (CALM) study. BMJ 2000;321:1440-1444.
33. Luıîo J, Barrio V, Goicoechea MA, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002;62(s82):47-52,
34. Myers B, Deen WM, Brenner BM, Effects of norepinephrine and angiotensin II on the deierminanis of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1975;37:101-110.
35. Miller PL, Rennke H, Meyer TW. Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol 1991;26l:F459-F465.
36. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77: 1925-1930.
37. Westenend PJ, Nooyen YA, Van der Krogl JA, et al. The effect of a converting enzyme inhibitor upon renal damage in
<)0
Türk
Nefroloji
, Diyaliz ve Transplantasyon Dergisi / Official Journal of the Turkish Society of Nephrology
Böbrek t iastalıklannırı Ted iv isinde Anjiyotensin Dönüştürücü Enzim tnhıbitörlen ve Anjiyotensin li Reseptör Bloktrlennın Kombıntsyonu ^jt
spontaneously hypertensive Fawn Hooded rats. J Hypertens 1992;10:417-422.
38. Sakemi T. Baba N, Yoshikawa Y. Angiotensin-converting enzyme inhibition attenuates hypercholesterolemia and glomerular injury in hyperlipidemic Imai rats. Nephron 1992; 62: 3H-321.
39. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy willi ACE inhibitors. Int J Radial Oncol Biol Phys 1993;27:93-99.
40. Anderson S, Rennke HG, Zalz R. Glomerular adaptations with normal aging and with long-term converting enzyme inhibition in rats. Am J Physiol 199i:267:F35-F43.
41. Lapinski R, Perico N, Remuzzi A. et al. Angiotensin II modulates glomerular capillary permselectiviiy in rat isolated perfused kidney. J Am Soc Nephrol 1996;7:653-660.
42. Kagami S. Border WA, Miller 1)E, el al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin invest 1994;93:2431-2437.
43- Kay PE. Bruggeman LA, Horikoshi S. et al. Angiotensin II stimulates human fetal mesangial cell proliferation and fibro-nectin biosynthesis by binding to ATI receptors. Kidney Int 1994;45:177-184.
Wolf G, Haberstroh LI, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am .1 Pathol 1992;140:95-107. •|S. Ara i M. Wada A, Isaka Y. el al. In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun 1995:206:525-^32.
46. Feener EP, Northrup JM. Aiello LP, et al. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 199S;95:1353-1362.
4-7. van Leeuwen RT, Kol A, Andreotti F, et al. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362-368.
•18. Vaughan DE, Lazos SA, long K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95;995-1001.
49, Baricos WH. Cortez SL, el-Dahr SS. Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA plasmin/MMP-2 cascade. Kidney Int 1995; 47:1039-1047.
50. Halin AW. Jonas U. Buhler ER. et al. Activation of human peripheral monocytes by angiotensin H. FEBS Lett 1994;347: 178-180.
5İ.
Fori
s G, Dezso B, Medgyesi GA. et al. Effect of angiotensin II on macrophage functions. Immunology 1983;48:529-535.
52. Keanc WF. Raij L. Relationship among altered glomerular barrier penîıselectivity, angiotensin 11, and mesangial uptake of macromolecules. Lab Invest 1985;52:599-604.
53. Weinstoek |V, Kassab JT. Angiotensin II stimulation of granuloma macrophage phagocytosis and a din polymerization in murine schistosomiasis mansoni. Cell Immunol 1984;89:46-54.
54. Greene EL, Kren S. Hostetler TH. Role of aldosterone in the remnant kidney model in the fat. J Clin Invest 1996;98:1063¬1068.
55. Lewis ET, Hunsicker LG, Bain RP, el al. The effect of" angi-otensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
56. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM parients with microalbuminuria. Diabetologia 1996;39:587-593-
57. Sano T, Kawamura T, Matsumae H, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994;17:420-424.
58. Trevİsan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients: North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995;8:876-883.
59. Sano T, Hotta N, Kawamura T, et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients; Results of a 4-year, prospective, randomized study. Diabet Med 1996;13:120-124.
60. Agardh CD, Garcia-Puig J, Charbonnel B. el al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril ıhan by nifedipine. J Hum Hypertens 1996;10:185-192.
61. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20:1576-1581.
62. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk palients. N Engl J Med 2000;342:145-153-
63. Maschio G, Albeni D, Janin G, et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-945.
64. Gruppo llaliano di Studi Epidemiologic^ in Nefrologia t GİŞEN). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
65. Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421; Angiotensin Il-renin relationships 10 evaluate efficacy of convening enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-972.
66. Arakawa K. Serine protease angiotensin II systems. J Hypertens 1996;14(Suppl 5):S3-S7.
67. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987;9:11142-11148.
68. Nishimura H, Hoffmann S, Baltatu O, eı al. Angioıensin I converting enzyme and cbymase in cardiovascular tissues. Kidney Int 1996;49(Suppl 55):S18-S23.
69- Urata H, Boehm KD, Philip A, el al. Cellular localization and regional distribution of an angiotensin ll-forming chymase in the bean. J Clin Invest 1993;91:1269-1281.
70. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. I Hypertension 1994;12tSuppl 9):S17-S22.
71. Clark KL, Robenson MJ, Drew GM. Role of angiotensin ATI and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog. Br J Pharmacol 1993:109:148¬156.
TND I. Hipertansiyon Kursu 2004, 13: Ek 2 / TSN Hypertension Course I 2004, 13: Suppİ 2
61
0
Böbrek Hastalıklarının Tedavisinde Anjiyotensin Dönüştürücü Enzim İnhibitörleri ve Anjiyotensin II Reseptör Blokerlerinin Kombinasyonu
72. Ardailloıı R. Angiotensin II receptors. J Am Sot Nephro! 1999; KXSuppI I I );S3(KS39.
73, Cluing Ö, Kuhl It. Stoll M, et al. Physiological and pharmacological implications of ATI versus AT2 receptors. Kidney Ini 1998-.S «Suppl (^];S<)S-S9lX
~~ s. Sliantntlgam S. l.lorens-Cortes C. Clauser E, et al. Expression of angiotensin II AT2 receptor mRNA during development of rat kidney and adrenal gland. Am .1 Physiol 1995; 268: F922-F930.
75; Nishimura H, Yerkes E, Hö İlen fel İner K. et al. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell 1999;3:1-10.
76. Sİragy IIM, Carey RA1. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious mis. j Clin Invest 1997;100:264-269
77. Siragy IIM, Carey RM. The subtype 2 angiotensin receptor regulates renal prostaglandin VI alpha formation in conscious rats. Am J Physiol 1997;273:R1 103-R 1107.
78. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinu-ric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 199:445:861-867.
79. Toto R, Shultz P, Raij 1., et al. Efficacy and tolerability of losartan İn hypertensive patients with renal impairment: Collaborative Group. Hypertension 1998;31:684-691.
80. Pitt B, Segal R. Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
81. del Castillo D, Campistol |M, Guirado L. et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998:54( Suppl 68):S135-S139.
82. Apperloo AJ, de Zeeuw D, de Jong PE. A shorl-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-797.
62